This study will test the hypothesis that implantation of a subcutaneous implantable cardioverter defibrillator (S-ICD) without performing a defibrillation test is non-inferior to S-ICD implant with a defibrillation test with regards to the primary endpoint failed first shock in a spontaneous arrhythmia episode when implant position is confirmed with PRAETORIAN score.
Implantable Cardioverter Defibrillator (ICD) implant improves survival in patients with a higher risk for sudden cardiac death. There are 2 types of ICD available; transvenous ICD (TV-ICD) and subcutaneous ICD (S-ICD). During ICD implant, defibrillation testing (DFT) is performed to test functionality of the device. However, DFT can be associated with complications such as inability to convert, complications arising from general anaesthesia, prolonged resuscitation, stroke and death. Whereas DFT may be associated with complications, the benefit of DFT is debated as literature shows there is only a modest average effect of DFT, if any, on mortality, shock efficacy or safety. Recently it was shown in a randomized controlled trial called 'SIMPLE' that routine defibrillation testing of TV-ICDs at the time of implant does not improve shock efficacy or reduce arrhythmic death. For S-ICD there is only limited data available of the effect of DFT on S-ICD efficacy. Data have however shown that the conversion efficacy of the S-ICD is comparable to TV-ICD. DFT is currently performed in standard S-ICD implants, but is omitted in specific cases. However, an alternative method to evaluate the correct position may be desired when omitting DFT. The PRAETORIAN Score is developed using computer modelling data on factors influencing defibrillation thresholds. The PRAETORIAN score represents the chance of a patient having an elevated defibrillation threshold and consequently failing a DFT or conversion of a spontaneous arrhythmia episode. The score was retrospectively validated in two studies with 180 and 321 patients. It was reported that most S-ICD implants are performed under general anesthesia, however other anesthesia protocols are used as well. One of the most predominant factors to use general anesthesia is the performance of the DFT. If this is omitted, other anesthesia protocols may be a good option for many patients as well.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
965
Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
Failed first appropriate shock in a spontaneous episode
Number of patients having experiences a failed first appropriate shock in a spontaneous arrhythmia episode
Time frame: 40 months
DFT related complications
Number of patients experiencing DFT related complications occurring within 24h or 30 days after DFT
Time frame: 24 hours or 30 days
PRAETORIAN Score
Implant position will be scored using the PRAETORIAN score
Time frame: up to 24 hours
Pain post implant
Pain score measured with McGill questionnaire
Time frame: 1-4 hours post implant
Appropriate ICD therapy
Shocks given for VT or VF
Time frame: 40 months
Inappropriate ICD therapy
Shocks given for anything else than VT or VF
Time frame: 40 months
Overall DFT conversion success
The percentage of patients with at least one induced episode teminated by an S-ICD shock within five seconds post shock delivery
Time frame: 40 months
Successful DFT
A successful DFT is defined as conversion to SR or AF in less than 5 seconds from appropriate shock delivery.
Time frame: 40 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Adventh Health System
Orlando, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
CorVita Science Foundation
Chicago, Illinois, United States
Englewood Hospital and Medical Center
Englewood, New Jersey, United States
Mount Sinai Beth Israel
New York, New York, United States
Icahn School of Medicine at Mount Sinaï
New York, New York, United States
Erlanger Health System
Chattanooga, Tennessee, United States
Asklepios Kliniken
Hamburg, Germany
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
Universitätsklinikum Schleswig-Holstein, Campus Lübeck
Lübeck, Germany
...and 22 more locations
Time to therapy
Time to therapy is the time between the start of VT or VF in a treated episode until the first shock in seconds.
Time frame: 40 months
Time to succesful therapy
Time to successful therapy is the time between the start of VT or VF until the first successful shock.
Time frame: 40 months
Shock efficacy
Percentage of appropriate shocks that was successfull
Time frame: 40 months
Conversion efficacy within 5 shocks in spontaneous episodes
Conversion efficacy within 5 shocks in spontaneous episodes
Time frame: 40 months
S-ICD related complications
S-ICD related complications requiring invasive intervention
Time frame: 40 months
MACE post DFT
Number of Major Adverse Cardiac Events after DFT procedure
Time frame: 30 days
Cardiac (pre-)syncope
Number of episodes of cardiac (pre-)syncope
Time frame: 40 months
Cardiac decompensation
Number of episodes of cardiac decompensation
Time frame: 40 months
Mortality
All cause mortality; arrhythmic death; cardiovascular death; unexplained death
Time frame: 40 months
Length of hospitalization
Length of hospitalization post implant (nights)
Time frame: 40 months
Device or lead repositioning
Number of procedures for device or lead repositioning
Time frame: 40 months
ICD related infection
Number of infections related to implanted ICD
Time frame: 40 months
Composite complications 30 days after implant
Number of patients experiencing complications occurring within 30 days after implant
Time frame: 30 days